The GPIQ ETF replicates the Nasdaq-100 index while selling covered calls on 25%-75% of its QQQ exposure to generate monthly income. Despite offering a yield above 10%, most of its distributions come from portfolio gains rather than dividends. With a low expense ratio of 0.29%, GPIQ competes well against peers and has delivered returns close to a mix of 85% QQQ and 15% T-Bills since launch. This suggests its active options strategy adds value without significantly sacrificing market upside potential.
The GPIQ ETF and its strategy are the subject here, with Pluang's market data providing context. For readers following US stocks, here is Pluang's market snapshot as of Oct 23, 2026 19:11 WIB: out of 150 priced US stocks, 38 rose and 109 fell. Notable movers include AT&T Inc. (T) at USD 21.60 with a 1-day change of -5.01%, Moderna, Inc. (MRNA) at USD 193.65 down 4.43%, and Verizon Communications Inc (VZ) at USD 43.26 down 4.29%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
